【综述】中草药与功能食品通过影响肠道菌群,从而对心血管病产生有益作用
  • 中草药与功能食品含有许多具有“益生元”活性的成分,如膳食纤维、多酚以及多糖;
  • 据报道,这些中草药与功能食品(成分)可以增加Akkermansia,Bifidobacteria,Lactobacillus,Bacteroides,Prevotella的丰富度,抑制Firmicutes,提高肠道中Firmicutes/Bacteroidetes比例;
  • 而这些菌群的代谢产物,如短链脂肪酸、胆汁酸、脂多糖以及(TMA)-N-oxide与心血管代谢疾病(CMD)有关;
  • 因此,肠道-器官轴可能可以作为治疗CMD的新靶点。
延伸阅读

Balancing Herbal Medicine and Functional Food for Prevention and Treatment of Cardiometabolic Diseases through Modulating Gut Microbiota

中草药与功能食品通过调节肠道菌群预防以及治疗心血管代谢疾病

10.3389/fmicb.2017.02146

2017-11-08, Review

Abstract & Authors:展开

Abstract:收起
It has become apparent that gut microbiota is closely associated with cardiometabolic diseases (CMDs), and alteration in microbiome compositions is also linked to the host environment. Next generation sequencing (NGS) has facilitated in-depth studies on the effects of herbal medicine and functional food on gut microbiota. Both herbal medicine and functional food contain fiber, polyphenols and polysaccharides, exerting prebiotics-like activities in the prevention and treatment of CMDs. The administrations of herbal medicine and functional food lead to increased the abundance of phylum Bacteroidetes, and genus Akkermansia, Bifidobacteria, Lactobacillus, Bacteroides and Prevotella, while reducing phylum Firmicutes and Firmicutes/Bacteroidetes ratio in gut. Both herbal medicine and functional food interact with gut microbiome and alter the microbial metabolites including short-chain fatty acids (SCFAs), bile acids (BAs) and lipopolysaccharides (LPS), which are now correlated with metabolic diseases such as type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD). In addition, trimethylamine (TMA)-N-oxide (TMAO) is recently linked to atherosclerosis (AS) and cardiovascular disease (CVD) risks. Moreover, gut-organs axes may serve as the potential strategy for treating CMDs with the intervention of herbal medicine and functional food. In summary, a balance between herbal medicine and functional food rich in fiber, polyphenols and polysaccharides plays a vital role in modulating gut microbiota (phylum Bacteroidetes, Firmicutes and Firmicutes/Bacteroidetes ratio, and genus Akkermansia, Bifidobacteria, Lactobacillus, Bacteroides and Prevotella) through SCFAs, BAs, LPS and TMAO signaling regarding CMDs. Targeting gut-organs axes may serve as a new therapeutic strategy for CMDs by herbal medicine and functional food in the future. This review aims to summarize the balance between herbal medicine and functional food utilized for the prevention and treatment of CMDs through modulating gut microbiota.

First Authors:
Ming Lyu

Correspondence Authors:
Yan Zhu

All Authors:
Ming Lyu, Yue-fei Wang, Guan-wei Fan, Xiao-ying Wang, Shuang-yong Xu , Yan Zhu

评论